Canaccord Genuity Maintains Buy on Kymera Therapeutics, Raises Price Target to $129

Benzinga Newsdesk www.benzinga.com Positive 84.7%

Neg 0% Neu 0% Pos 84.7%

Canaccord Genuity analyst Edward Nash maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $106 to $129.